ABSTRACT
Careful pharmacologic manipulation of the host immune system to prevent rejection of the lung allograft remains the cornerstone of management following lung transplantation. This immunologic imperative must in turn be balanced with the need to avoid significant infection. The immunosuppressive regimens used and extent of immunosuppression achieved have a critical effect on the infection and rejection profiles of individuals undergoing lung transplantation, which in turn affects their long-term survival.
